Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab
- 27 November 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (2), 551-555
- https://doi.org/10.1111/bjd.15631
Abstract
Here we report the case of a psoriasis patient who developed an ulcerative colitis (UC) most likely caused by Adalimumab. After cessation of Adalimumab, colitis improved significantly. However, since psoriasis worsened, the patient was switched to Ustekinumab which resulted in complete cessation of colitis. During the two-year follow-up under Ustekinumab therapy no further gastrointestinal complaints occurred. Paradoxical psoriasis manifestations in inflammatory bowel disease (IBD) under TNF-inhibitor therapy have been reported and rarely paradoxical IBD occurred (mostly Crohn's disease) in rheumatologic patients treated with Infliximab or Etanercept. Due to the highly probable association of Adalimumab with the onset of colitis in this case, we would like to suggest the term of paradoxical ulcerative colitis (PUC) for this yet only extremely scarcely reported phenomenon. To the best of our knowledge this is the first description of a paradoxical UC in a psoriasis patient and in Adalimumab treatment. Our observation suggests that Ustekinumab is an effective treatment option in patients with paradoxical anti-TNF driven inflammatory reactions like psoriasis or inflammatory bowel disease.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A-146940)
This publication has 19 references indexed in Scilit:
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2016
- Swiss S1 Guidelines on the Systemic Treatment of Psoriasis VulgarisDermatology, 2016
- Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort studyBritish Journal of Dermatology, 2016
- Adverse reactions to biologic agents and their medical managementNature Reviews Rheumatology, 2014
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut, 2013
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's DiseaseNew England Journal of Medicine, 2012
- Paradoxical inflammation induced by anti-TNF agents in patients with IBDNature Reviews Gastroenterology & Hepatology, 2012
- Ulcerative ColitisNew England Journal of Medicine, 2011
- Role of biological therapy for inflammatory bowel disease in developing countriesGut, 2011
- Psoriasis associated with ulcerative colitis and Crohn's diseaseJournal of the European Academy of Dermatology and Venereology, 2009